Eurasian Journal of Pulmonology

LETTER TO EDITOR
Year
: 2020  |  Volume : 22  |  Issue : 1  |  Page : 70-

Proadrenomedullin and prognostic value for pneumonia


Beuy Joob1, Viroj Wiwanitkit2,  
1 Sanitation 1 Medical Academic Center, Bangkok, Thailand
2 Department of Community Medicine, Dr. DY Patil University, Pune, Maharashtra, India

Correspondence Address:
Dr. Beuy Joob
Sanitation 1 Medical Academic Center, Bangkok
Thailand




How to cite this article:
Joob B, Wiwanitkit V. Proadrenomedullin and prognostic value for pneumonia.Eurasian J Pulmonol 2020;22:70-70


How to cite this URL:
Joob B, Wiwanitkit V. Proadrenomedullin and prognostic value for pneumonia. Eurasian J Pulmonol [serial online] 2020 [cited 2020 Oct 21 ];22:70-70
Available from: https://www.eurasianjpulmonol.com/text.asp?2020/22/1/70/283633


Full Text



Dear Editor,

We read the publication on “Proadrenomedullin (proADM) determining clinical severity and analyzing prognostic value for pneumonia” with a great interest.[1] Demirsoy et al. concluded that “Using proADM levels alone to predict pneumonia prognosis and mortality and deciding upon a therapy setting make no sense, although in consideration of previous studies, proADM would be useful as a supplementary contributor to clinical severity scores.[1]” Indeed, the diagnostic value of proADM in pneumonia is interesting. Several reports, including to the present report, show that proADM might be useful. Nevertheless, there are many important considerations. First, proADM might be altered due to other medical underlying factors. The heart disease is another important medical problem that can result in alteration on proADM level.[2] Furthermore, other underlying lung disease such as chronic obstructive lung disease can also result in alteration of proADM level.[3]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Demirsoy S, Okutan O, Kartaloglu Z, Tas D, Ayten O, Canoglu K. Proadrenomedullin determining clinical severity and analyzing prognostic value for pneumonia. Eurasian J Pulmonol 2019;21:97-106.
2Nishikimi T, Nakagawa Y. Adrenomedullin as a biomarker of heart failure. Heart Fail Clin 2018;14:49-55.
3Schuetz P, Marlowe RJ, Mueller B. The prognostic blood biomarker proadrenomedullin for outcome prediction in patients with chronic obstructive pulmonary disease (COPD): A qualitative clinical review. Clin Chem Lab Med 2015;53:521-39.